申请人:TAIHO PHARMACEUTICAL CO., LTD.
公开号:US20210177826A1
公开(公告)日:2021-06-17
An antitumor formulation comprising a biphenyl compound having LSD1 inhibitory activity or a salt thereof and one or more other antitumor agents that are administered in combination, the compound being represented by Formula (I):
wherein ring A, ring B, R1 to R6, l, m, and n are as defined in the specification.